Literature DB >> 9156766

A relationship between TGF-beta 1 or IL-6 plasma levels and clinical features of spondyloarthropathies.

P Claudepierre, J C Rymer, F J Authier, Y Allanore, B Larget-Piet, R Gherardi, X Chevalier.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9156766     DOI： 10.1093/rheumatology/36.3.400

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN： 0263-7103


× No keyword cloud information.
  11 in total

1.  Preferential type 1 chemokine receptors and cytokine production of CD28- T cells in ankylosing spondylitis.

Authors:  C Duftner; C Dejaco; W Kullich; A Klauser; C Goldberger; A Falkenbach; M Schirmer
Journal:  Ann Rheum Dis       Date:  2005-10-11       Impact factor: 19.103

Review 2.  The synovio-entheseal complex in enthesoarthritis.

Authors:  Angelo De Cata; Michele Inglese; Rosa Rubino; Francesca Molinaro; Gianluigi Mazzoccoli
Journal:  Clin Exp Med       Date:  2015-02-12       Impact factor: 3.984

3.  Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis.

Authors:  L Gossec; D van der Heijde; A Melian; D A Krupa; M K James; P F Cavanaugh; A S Reicin; M Dougados
Journal:  Ann Rheum Dis       Date:  2005-02-24       Impact factor: 19.103

4.  Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases.

Authors:  R J François; L Neure; J Sieper; J Braun
Journal:  Ann Rheum Dis       Date:  2005-10-25       Impact factor: 19.103

5.  Aberrant TGF-β activation in bone tendon insertion induces enthesopathy-like disease.

Authors:  Xiao Wang; Liang Xie; Janet Crane; Gehua Zhen; Fengfeng Li; Ping Yang; Manman Gao; Ruoxian Deng; Yiguo Wang; Xiaohua Jia; Cunyi Fan; Mei Wan; Xu Cao
Journal:  J Clin Invest       Date:  2018-01-22       Impact factor: 14.808

6.  Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis.

Authors:  A Bal; E Unlu; G Bahar; E Aydog; E Eksioglu; R Yorgancioglu
Journal:  Clin Rheumatol       Date:  2006-04-01       Impact factor: 2.980

7.  Blood levels of transforming growth factor-beta 1 (TGF-beta1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta 1b (IFN-beta1b).

Authors:  F Nicoletti; R Di Marco; F Patti; E Reggio; A Nicoletti; P Zaccone; F Stivala; P L Meroni; A Reggio
Journal:  Clin Exp Immunol       Date:  1998-07       Impact factor: 4.330

Review 8.  Cytokines in the seronegative spondyloarthropathies and their modification by TNF blockade: a brief report and literature review.

Authors:  C Keller; A Webb; J Davis
Journal:  Ann Rheum Dis       Date:  2003-12       Impact factor: 19.103

9.  Association of cytokine and matrix metalloproteinase profiles with disease activity and function in ankylosing spondylitis.

Authors:  Derek L Mattey; Jonathan C Packham; Nicola B Nixon; Lucy Coates; Paul Creamer; Sarah Hailwood; Gordon J Taylor; Ashok K Bhalla
Journal:  Arthritis Res Ther       Date:  2012-05-28       Impact factor: 5.156

10.  Is IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? A multicentre retrospective observational study.

Authors:  Fernando Kemta Lekpa; Cécile Poulain; Daniel Wendling; Martin Soubrier; Michel De Bandt; Jean Marie Berthelot; Philippe Gaudin; Eric Toussirot; Philippe Goupille; Thao Pham; Jérémie Sellam; Rémy Bruckert; Muriel Paul; Valérie Farrenq; Pascal Claudepierre
Journal:  Arthritis Res Ther       Date:  2012-03-09       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.